Small Molecules
7 November 2016
Actelion announces positive results of the MERIT study with macitentan in patients with chronic thromboembolic pulmonary hypertension7 November 2016
Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer4 November 2016
Innocoll Announces Top-Line Data From Phase 3 Trials With COGENZIA and NDA Submission for XARACOLL4 November 2016
ACADIA Pharmaceuticals Initiates Phase III Trial of Pimavanserin for Adjunctive Treatment in Patients with Schizophrenia2 November 2016
Tesaro Announces Submission of Niraparib New Drug Application for Platinum-Sensitive, Recurrent Ovarian Cancer1 November 2016
Lynparza® (olaparib) phase III SOLO-2 trial shows significant progression-free survival benefit for women with ovarian cancer1 November 2016
Medivir’s Nucleotide Polymerase Inhibitor for the Treatment of Liver Cancer, MIV-818, Enters Non-Clinical Development1 November 2016
Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer31 October 2016
Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50001 to Treat Alopecia Universalis and Alopecia Totalis31 October 2016
ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Brigatinib31 October 2016
ACADIA Pharmaceuticals Initiates Phase II Study of Pimavanserin in Alzheimer’s Disease Agitation31 October 2016
Vyome Biosciences Administers First In-human Dose of VB 1953 in U.S. Phase 1 Clinical Study in Patients with Facial Acne Vulgaris31 October 2016
Enrollment commences in phase III clinical study of Eisai’s BACE inhibitor E2609 in early Alzheimer’s disease31 October 2016
ReViral Initiates Phase 1 Clinical Trial of Potent Oral Inhibitor Against Respiratory Syncytial Virus27 October 2016
Results from Shire’s Phase 2 Study of Maribavir Showed Activity Against CMV Infection in Patients Undergoing Transplant27 October 2016
Inclusion of the First Patient in the Phase II Clinical Study That Aims to Test THN102 in Patients Affected by NarcolepsyNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
SubscribeNewsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
SubscribeFeatured reports